Long-Term Organ Damage: Anifrolumab versus Real-World Standard of Care in Adult Patients with Active Systemic Lupus Erythematosus

Trial Identifier: D3461R00077
Sponsor: AstraZeneca
Collaborator:
IQVIA Ltd
University Health Network
Start Date: May 2024
Primary Completion Date: June 2025
Study Completion Date: June 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Canada, Ontario Toronto, Ontario, Canada, M5G 1L7